Silicon Motion Technology maintains a Strong Buy rating with a revised price target of $409 per ADS, driven by accelerated growth in enterprise and AI storage segments. Revenue from Ferri and Enterprise Boot Drive solutions surged to nearly 30%, up from 4% a year ago, significantly strengthening the investment thesis. Despite slower PCIe Gen5 adoption, rapid scaling in key products supports a 2027 EPS estimate of $15.13. The stock trades at a premium valuation justified by sector-leading earnings growth and a conservative approach to risks.
Silicon Motion's recent price target update is presented here with Pluang's Technology sector data as of Sep 17, 2026 17:41 WIB: out of 150 priced US tech stocks, 133 rose and 14 fell. Notable movers include FIVN at USD 31.71 with a 6.95% decline and NOK at USD 10.75 with a 6.02% gain. The most notable figure is NOK's 6.02% increase.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
